BRIEF: WuXi AppTec sells advanced therapies units in U.K. and U.S.
Leading pharmaceutical research outsourcing company WuXi AppTec Co. Ltd. (2359.HK; 603259.SH), announced on Tuesday that it has agreed to transfer its entire equity stakes in Advanced Therapies and Oxford Genetics…
WuXi AppTec mulls gene unit sale to soften U.S. legal blow
Market talk is swirling that WuXi AppTec may be preparing to shed its cell and gene therapy business to limit potential exposure to U.S. biosecurity legislation Key Takeaways: The drug…
WuXi AppTec posts lower profits but avoids more share price pain
The pharmaceutical services giant delivered lackluster half-year earnings, with revenues and profits both falling, but investors were relieved that its U.S. business took only a minor hit Key Takeaways: U.S.…
CHINA BULLETIN: U.S. Ratchets Up Strategic Tariffs
In this week’s issue strategic China tariffs from Washington, ‘Big Short’ investor buys China stocks and a diaper maker finds riches in Russia. On a scale of 1 to 100,…
China-focused Tigermed staves off biopharma gloom
Investors have not been deterred by an earnings slide, wagering that the drugs services company is better placed to weather an industry storm than some biopharma stocks Key Takeaways: Tigermed…
Recent Articles
BRIEF: WuXi AppTec sells advanced therapies units in U.K. and U.S.
2359.HK
603259.SHG
WuXi AppTec mulls gene unit sale to soften U.S. legal blow
2359.HK
603259.SHG
WuXi AppTec posts lower profits but avoids more share price pain
2359.HK
603259.SHG
China-focused Tigermed staves off biopharma gloom
3347.HK
300347.SHE
RELATED ARTICLES
-
WuXi AppTec mulls gene unit sale to soften U.S. legal blow
2359.HK 603259.SHG
-
WuXi AppTec posts lower profits but avoids more share price pain
2359.HK 603259.SHG
-
Potential U.S. targeting casts shadow over WuXi AppTec family
2359.HK 603259.SHG
-
U.S. rethinks timing of biotech crackdown, easing pressure on WuXi family
2269.HK 2359.HK 2268.HK
-
GenScript losses shrink on strong growth for cancer cell therapy
1548.HK
- Increasing losses prompt Zephyrm Bioscience to seek funds through IPO
